Literature DB >> 19387556

Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent.

Mi Kyung Kwak1, Keun Hur, Ji Eun Yu, Tae Su Han, Kazuyoshi Yanagihara, Woo Ho Kim, Sun Mi Lee, Soo-Chang Song, Han-Kwang Yang.   

Abstract

Current systemic chemotherapy in the treatment of solid tumors inevitably induces various systemic adverse effects. Locally injected chemotherapy is expected to overcome this limitation of systemic therapy. We evaluated by luminescence imaging the effects of chemotherapy administered locally by means of a biodegradable thermosensitive hydrogel polymer. The human gastric cancer cell line HSC44Luc was used for tumor induction, and it was confirmed to be sensitive to doxorubicin by MTT assay. Cells were injected subcutaneously into Balb/c-nude mice. When the mean volume of tumor reached 400 mm(3), we divided the mice into 6 groups (5 per group) according to treatment: 1) control (intratumor injection of PBS), 2) systemic injection of doxorubicin, 3) intratumor injection of polymer gel, 4) intratumor injection of polymer gel physically mixed with a low dose of doxorubicin, 5) intratumor injection of polymer gel physically mixed with a high dose of doxorubicin, 6) intratumor injection of conjugated polymer gel with doxorubicin. Body weight and tumor volume were measured every 2 or 3 days for 30 days after treatment. One mouse in each group was sacrificed for histopathologic examination every week. Reductions in body weight were not significantly different among groups. The relative rate of tumor growth was 774% in Group 1, 267% in Group 2, 813% in Group 3, -186% in Group 4, and 155% in Group 6, respectively. Thus the relative rate of tumor growth in the groups treated with polymer gel mixed with doxorubicin and the groups treated with conjugated polymer gel with doxorubicin were lower than that in the control group. Locally injectable chemotherapy using a thermosensitive hydrogel polymer with doxorubicin can suppress tumor growth effectively without severe systemic toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387556     DOI: 10.1007/s10637-009-9253-5

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  17 in total

Review 1.  Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.

Authors:  A H Partridge; H J Burstein; E P Winer
Journal:  J Natl Cancer Inst Monogr       Date:  2001

Review 2.  Side effects of adjuvant treatment of breast cancer.

Authors:  C L Shapiro; A Recht
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

3.  Biodegradable block copolymers as injectable drug-delivery systems.

Authors:  B Jeong; Y H Bae; D S Lee; S W Kim
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

Review 4.  Carcinogenic effects of chemotherapeutic compounds.

Authors:  A J Klein-Szanto
Journal:  Prog Clin Biol Res       Date:  1992

Review 5.  Nanomedicine for respiratory diseases.

Authors:  Ulrich Pison; Tobias Welte; Michael Giersig; David A Groneberg
Journal:  Eur J Pharmacol       Date:  2006-01-24       Impact factor: 4.432

Review 6.  Toxicity of chemotherapy.

Authors:  R M Lowenthal; K Eaton
Journal:  Hematol Oncol Clin North Am       Date:  1996-08       Impact factor: 3.722

7.  Report on the use of poly(organophosphazenes) for the design of stimuli-responsive vesicles.

Authors:  Anne-Claude Couffin-Hoarau; Jean-Christophe Leroux
Journal:  Biomacromolecules       Date:  2004 Nov-Dec       Impact factor: 6.988

8.  Controlled release of doxorubicin from thermosensitive poly(organophosphazene) hydrogels.

Authors:  Gyung D Kang; Se H Cheon; Soo-Chang Song
Journal:  Int J Pharm       Date:  2006-04-01       Impact factor: 5.875

9.  Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease.

Authors:  Alison E John; Nicholas W Lukacs; Aaron A Berlin; Aiyappa Palecanda; Robert F Bargatze; Lloyd M Stoolman; Jon O Nagy
Journal:  FASEB J       Date:  2003-10-16       Impact factor: 5.191

10.  Synthesis and antitumor activity of novel thermosensitive platinum(II)-cyclotriphosphazene conjugates.

Authors:  Soo-Chang Song; Sang Beom Lee; Bae Hoon Lee; Hyung-Wook Ha; Kyung-Tae Lee; Youn Soo Sohn
Journal:  J Control Release       Date:  2003-07-31       Impact factor: 9.776

View more
  5 in total

1.  Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer.

Authors:  Shigenobu Emoto; Hironori Yamaguchi; Takao Kamei; Hironori Ishigami; Takashi Suhara; Yukimitsu Suzuki; Taichi Ito; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2013-07-26       Impact factor: 2.549

Review 2.  Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Shigenobu Emoto; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-02-01       Impact factor: 2.549

3.  The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.

Authors:  Jieun Yu; Hyuk-Joon Lee; Keun Hur; Mi Kyung Kwak; Tae Su Han; Woo Ho Kim; Soo-Chang Song; Kazuyoshi Yanagihara; Han-Kwang Yang
Journal:  Invest New Drugs       Date:  2010-07-29       Impact factor: 3.850

4.  Simultaneous monitoring of the drug release and antitumor effect of a novel drug delivery system-MWCNTs/DOX/TC.

Authors:  Xia Dong; Zhiting Sun; Xiaoxiao Wang; Dunwan Zhu; Lanxia Liu; Xigang Leng
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 5.  Injectable Hydrogels for Cancer Therapy over the Last Decade.

Authors:  Giuseppe Cirillo; Umile Gianfranco Spizzirri; Manuela Curcio; Fiore Pasquale Nicoletta; Francesca Iemma
Journal:  Pharmaceutics       Date:  2019-09-19       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.